Significance of the fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer

American Journal of Pathology

Volumn 176, Issue 6, 2010, Pages 2935-2947

  Rudland, Philip S ^a   Platt Higgins, Angela M ^a   Davies, Lowri M ^a   Rudland, Suzete De Silva ^a   Wilson, James B ^a   Aladwani, Abdulaziz ^a   Winstanley, John H R ^b   Barraclough, Dong L ^a   Barraclough, Roger ^a   West, Christopher R ^a   Jones, Nigel J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL BOLTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALVASCULIN; FANCONI ANEMIA GROUP D2 PROTEIN; OSTEOPONTIN; PROTEIN S 100; FANCD2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOPLASM; FANCONI ANEMIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; WILCOXON SIGNED RANKS TEST; AGED; BREAST NEOPLASMS; CELL CULTURE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELLS, CULTURED; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL RATE;

EID: 77953206453     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090779     Document Type: Article

References (65)

1. Barraclough DL, Platt-Higgins A, de Silva Rudland S, Barraclough R, Winstanley JHR, West CR, Rudland PS: The metastasis associated Anterior Gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol 2009, 175:1848-1857
2. Rudland PS, Platt-Higgins A, Renshaw C, West CR, Winstanley JHR, Robertson L, Barraclough R: Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 2000, 60:1595-1603 (Pubitemid 30183430)
3. Rudland PS, Platt-Higgins A, El-Tanani M, Rudland SDS, Barraclough R, Winstanley JHR, Howitt R, West CR: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002, 62:3417-3427 (Pubitemid 34651388)
4. Wang GZ, Platt-Higgins A, Carroll J, Rudland SD, Winstanley J, Barraclough R, Rudland PS: Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 2006, 66:1199-1207
5. Boulton SJ: Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Transact 2006, 34:633-645
6. Nagaraju G, Scully R: Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks. DNA Repair 2007, 6:1018-1031
7. Thompson LH, Hinz JM: Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mut Res/Fund Mol Mech Mutagenesis 2009, 668:54-72
8. Wang WD: Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748
9. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, de Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609
10. Alter BP: Cancer in Fanconi anemia, 1927-2001. Cancer 2003, 97:425-440
11. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001, 7:249-262
12. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD: S-phase-specific interaction of the Fanconi anemia protein. FANCD2, with BRCA1 and RAD51. Blood 2002, 100:2414-2420
13. Wang XZ, Andreassen PR, D'Andrea AD: Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004, 24:5850-5862
14. de Oca RM, Andreassen PR, Margossian SP, Gregory RC, Taniguchi T, Wang XZ, Houghtaling S, Grompe M, D'Andrea AD: Regulated interaction of the Fanconi anemia protein. FANCD2, with chromatin. Blood 2005, 105:1003-1009
15. Alpi A, Langevin F, Mosedale G, Machida YJ, Dutta A, Patel KJ: UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: a basis for the regulation of FANCD2 monoubiquitination. Mol Cell Biol 2007, 27:8421-8430
16. Bagby GC, Alter BP: Fanconi anemia. Sem Hematol 2006, 43: 147-156
17. Patel KJ: Fanconi anemia and breast cancer susceptibility. Nat Genet 2007, 39:142-143
18. Walsh T, King MC: Ten genes for inherited breast cancer. Cancer Cell 2007, 11:103-105
19. Hussain S, Wilson JB, Medhurst AL, Hejna J, Witt E, Ananth S, Davies A, Masson JY, Moses R, West SC, de Winter JP, Ashworth A, Jones NJ, Mathew CG: Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet 2004, 13:1241-1248
20. Wilson JB, Yamamoto K, Marriott AS, Hussain S, Sung P, Hoatlin ME, Mathew CG, Takata M, Thompson LH, Kupfer GM, Jones NJ: FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene 2008, 27:3641-3652
21. Houghtaling S, Timmers C, Noll M, Finegold MJ, Jones SN, Meyn MS, Grompe M: Epithelial cancer in Fanconi anemia complementation group D2 (FancD2) knockout mice. Genes Dev 2003, 17:2021-2035
22. Pejovic T, Yates JE, Liu HY, Hays LE, Akkari Y, Torimaru Y, Keeble W, Rathbun RK, Rodgers WH, Bale AE, Ameziane N, Zwaan CM, Errami A, Thuillier P, Cappuccini F, Olson SB, Cain JM, Bagby GC: Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer. Cancer Res 2006, 66:9017-9025
23. Mathew CG: Fanconi anaemia genes and susceptibility to cancer. Oncogene 2006, 25:5875-5884
24. van der Groep P, Hoelzel M, Buerger H, Joenje H, de Winter JP, van Diest PJ: Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer. Breast Cancer Res Treatment 2008, 107:41-47
25. Anandappa SY, Winstanley JHR, Leinster S, Green B, Rudland PS, Barraclough R: Comparative expression of fibroblast growth factor messenger RNAs in benign and malignant breast disease. Br J Cancer 1994, 69:772-776 (Pubitemid 24112704)
26. Winstanley JHR, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM, Rudland PS: Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer 1993, 67:767-772 (Pubitemid 23101556)
27. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R: Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005, 65:3796-3805
28. Rudland PS, Ollerhead G, Barraclough R: Isolation of Simian virus 40 transformed human mammary epithelial stem cell lines that can differentiate to myoepithelial-like cells in culture and in vivo. Dev Biol 1989, 136:167-180
29. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527
30. Zhi G, Wilson JB, Chen X, Krause DS, Xiao Y, Jones NJ, Kupfer GM: Fanconi Anemia complementation group FANCD2 protein serine 331 phosphorylation is important for Fanconi Anemia pathway function and BRCA2 interaction. Cancer Res 2009, 69:8775-8783
31. Mi J, Qiao F, Wilson JB, High AA, Schroeder MJ, Stukenberg PT, Moss A, Shabanowitz J, Hunt DF, Jones NJ, Kupfer GM: FANCG is phosphorylated at serines 383 and 387 during mitosis. Mol Cell Biol 2004, 24:8576-8585
32. Timmers C, Taniguchi T, Hejna J, Reifsteck C, Lucas L, Bruun D, Thayer M, Cox B, Olson S, D'Andrea AD, Moses R, Grompe M: Positional cloning of a novel Fanconi anemia gene, FANCD2. Molecular Cell 2001, 7:241-248
33. Collins NB, Wilson JB, Bush T, Thomashevski A, Roberts KJ, Jones NJ, Kupfer GM: ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Blood 2009, 113:2181-2190
34. Jones NJ, Ellard S, Waters R, Parry EM: Cellular and chromosomal hypersensitivity to DNA cross-linking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants-phenotypic similarities to ataxia-telangiectasia and Fanconi's anemia cells. Carcinogenesis 1993, 14:2487-2494 (Pubitemid 24016583)
35. Scott D, Dean BJ, Danford ND, Kirkland DJ: Metaphase chromosome aberration assays in vitro. Basic Mutagenicity Tests: UKEMS recommended procedures. Edited by DJ Kirkland. Cambridge, Cambridge University Press, 1990, pp 62-86
36. Gusterson BA, Warburton MJ, Mitchell D, Ellison M, Neville AM, Rudland PS: Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. Cancer Res 1982, 42:4763-4770 (Pubitemid 13205987)
37. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, Pieri F, Fraternali-Orcioni G, Pileri SA: The EnVision (TM)+ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate (TM), CSA, LABC, and SABC techniques. J Clin Pathol 1998, 51:506-511
38. Platt-Higgins AM, Renshaw CA, West CR, Winstanley JHR, Rudland SD, Barraclough R, Rudland PS: Comparison of the metastasis-inducing protein S100A4 (p9Ka) with other prognostic markers in human breast cancer. Int J Cancer 2000, 89:198-208 (Pubitemid 30185931)
39. Kilty IC, Barraclough R, Schmidt G, Rudland PS: Isolation of a potential neural stem cell line from the internal capsule of an adult transgenic rat brain. J Neurochem 1999, 73:1859-1870 (Pubitemid 29491799)
40. Altman D: Practical statistics for medical research. London, Chapman and Hall, 1991, pp 371-375
41. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991, 63:447-450
42. Cox DR: Regression models and life-tables. J Royal Stat Soc Ser B-Stat Methodol 1972, 34:187-220
43. Wilson JB, Johnson MA, Stuckert AP, Trueman KL, May S, Bryant PE, Meyn RE, D'Andrea AD, Jones NJ: The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange. Carcinogenesis 2001, 22:1939-1946 (Pubitemid 34065387)
44. Auerbach AD: Fanconi anemia and its diagnosis. Mut Res/Fund Mol Mech Mutagenesis 2009, 668:4-10
45. Hoelzel M, van Diest PJ, Bier P, Wallisch M, Hoatlin ME, Joenje H, de Winter JP: FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anaemia. J Pathol 2003, 201:198-203
46. Patel KJ, Joenje H: Fanconi anemia and DNA replication repair. DNA Repair 2007, 6:885-890
47. Plo I, Laulier C, Gauthier L, Lebrun F, Calvo F, Lopez BS: AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res 2008, 68:9404-9412
48. Barroso E, Milne RL, Fernandez LP, Zamora P, Arias JI, Benitez J, Ribas G: FANCD2 associated with sporadic breast cancer risk. Carcinogenesis 2006, 27:1930-1937
49. Wang XZ, Kennedy RD, Ray K, Stuckert P, Ellenberger T, D'Andrea AD: Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol 2007, 27:3098-3108
50. Ho GPH, Margossian S, Taniguchi T, D'Andrea AD: Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol 2006, 26:7005-7015
51. Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST, Lane WS, Kastan MB, D'Andrea AD: Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002, 109:459-472
52. Thompson LH, Hinz JM, Yamada NA, Jones NJ: How Fanconi anemia proteins promote the four Rs: replication, recombination, repair, and recovery. Environ Mol Mutagenesis 2005, 45:128-142
53. Lyakhovich A, Surralles J: FANCD2 depletion sensitizes cancer cells repopulation ability in vitro. Cancer Lett 2007, 256:186-195
54. Henderson BR: Regulation of BRCA1. BRCA2 and BARD1 intracellular trafficking. Bioessays 2005, 27:884-893
55. Thomashevski A, High AA, Drozd M, Shabanowitz J, Hunt DF, Grant PA, Kupfer GM: The Fanconi anemia core complex forms four complexes of different sizes in different subcellular compartments. J Biol Chem 2004, 279:26201-26209
56. Bagby GC: The less-traveled Fanconi road. Blood 2006, 107: 4196-4197
57. Bagby G, Keeble W, Koretsky T, Zodrow D, Jove R, Hays L, Carlson H: Oxidative stress induces binding of FANCD2 to STAT5 and facilitates STAT5-dependent survival signals. Blood 2004, 104:13A-14A
58. Pagano G, Degan P, d'Ischia M, Kelly FJ, Nobili B, Pallardo FV, Youssoufian H, Zatterale A: Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype. Eur J Haematol 2005, 75:93-100
59. Nicolson GL, Conklin KA: Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin Exp Metastasis 2008, 25:161-169
60. Willers H, Kachnic LA, Luo CM, Li L, Purschke M, Borgmann K, Held KD, Powell SN: Biomarkers and mechanisms of FANCD2 function. J Biomedicine Biotechnol 2008, Article ID 821529:doi:10.1155/2008/821529
61. Zhang QS, Eaton L, Snyder ER, Houghtaling S, Mitchell JB, Finegold M, van Waes C, Grompe M: Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. Cancer Res 2008, 68:1601-1608
62. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer 2007, 96:1504-1513
63. Davies BR, Davies MPA, Gibbs FEM, Barraclough R, Rudland PS: Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9ka, a rat calcium binding protein, but not with the oncogene EJ-Ras-1. Oncogene 1993, 8:999-1008 (Pubitemid 23087433)
64. Oates AJ, Barraclough R, Rudland PS: The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996, 13:97-104 (Pubitemid 26248549)
65. Jackson SP: The DNA-damage response: new molecular insights and new approaches to cancer therapy. Biochem Soc Transact 2009, 37:483-494.